摘要
目的回顾性分析高危局限进展性肾透明细胞癌(ccRCC)术后辅助应用干扰素-α预防术后肿瘤复发和进展的效果。方法对1999年至2007年华西医院泌尿外科176例高危局限进展性ccRCC患者的资料进行分析。其中79例(治疗组)患者术后予常规处理加干扰素-α进行辅助治疗,97例(对照组)患者术后行常规处理。分析两组患者无进展生存期(PFS)和总生存期(OS)的差异性及其影响因素。结果随访中位时间为48月。176例患者中,发生进展53例(30.11%),死亡37例(21.02%),治疗组患者肿瘤复发率高于对照组(44.3%vs.18.6%,P<0.001)。单因素分析结果显示,治疗组患者的PFS短于对照组〔(59.12±5.04)月vs.(81.42±5.84)月,P=0.005〕;治疗组的OS同样短于对照组〔(74.66±4.77)月vs.(85.18±4.92)月,P=0.031〕。多因素分析显示,该类药物的使用是影响高危局限进展性肾细胞癌患者生存的独立危险因素。结论高危局限进展性肾透明细胞癌术后应用干扰素-α辅助治疗不能预防术后肿瘤复发及进展,目前没有临床证据支持干扰素-α可以作为肾癌术后的辅助用药。
Objective To evaluate the effect of interferon-alpha（IFN-α） on locally advanced clear cell renal cell carcinoma（ccRCC） after radical nephrectomy in terms of tumor progression free survival（PFS） and overall survival（OS）.Methods 176 cases with locally advanced ccRCC were followed up in West China Hospital from 1999 to 2007.All patients were divided into two groups according to whether treated with IFN-α as adjuvant therapy.PFS and OS were analyzed with Kaplan-Meier method and Cox regression model.Results Median follow-up was 48 months,53 cases of disease progressed,and 37 were dead.Mortality rate within treatment and observed groups were 44.3% and 18.6%,respectively（P〈0.001）.There were significant differences between the two groups in PFS（（59.12±5.04） months vs.（81.42±5.84） months,P=0.005） and OS（（74.66±4.77） months vs.（85.18±4.92） months,P=0.031）.Cox regression model demonstrated that IFN-α,as adjuvant therapy after surgery,was an independent negative risk factor for the prognosis of locally advanced clear cell renal cell carcinoma.Conclusion IFN-α was ineffective in locally advanced ccRCC after radical nephrectomy in terms of PFS and OS,and there is no evidence that IFN-α could be considered as adjuvant therapeutic drug.
出处
《四川大学学报（医学版）》
CAS
CSCD
北大核心
2012年第1期91-94,共4页
Journal of Sichuan University(Medical Sciences)
关键词
肾透明细胞癌
辅助治疗
干扰素-Α
疗效
Clear cell renal cell carcinoma Adjuvant therapy Interferon-α Treatment effect
